see more

The Bayer AG logo sits on the exterior of the drugmaker's offices in Berlin, Germany, on Friday, Dec. 1, 2017. Bayer is ready to spend more money on deals and research that will help make it into a cancer company as the companys blockbuster blood-thinner Xarelto nears the final years of its patent life. Photographer: Krisztian Bocsi/Bloomberg via Getty Images

The Bayer AG logo sits on the exterior of the drugmaker's offices in Berlin, Germany, on Friday, Dec. 1, 2017. Bayer is ready to spend more money on deals and research that will help make it into a cancer company as the companys blockbuster blood-thinner Xarelto nears the final years of its patent life. Photographer: Krisztian Bocsi/Bloomberg via Getty Images

see more

Dieter Weinand, head of pharmaceuticals at Bayer AG, speaks during an interview at the drugmaker's offices in Berlin, Germany, on Friday, Dec. 1, 2017. Bayer is ready to spend more money on deals and research that will help make it into a cancer company as the companys blockbuster blood-thinner Xarelto nears the final years of its patent life. Photographer: Krisztian Bocsi/Bloomberg via Getty Images

Dieter Weinand, head of pharmaceuticals at Bayer AG, speaks during an interview at the drugmaker's offices in Berlin, Germany, on Friday, Dec. 1, 2017. Bayer is ready to spend more money on deals and research that will help make it into a cancer company as the companys blockbuster blood-thinner Xarelto nears the final years of its patent life. Photographer: Krisztian Bocsi/Bloomberg via Getty Images

see more

Joerg Moeller, head of development at Bayer AG, speaks during a news conference at the drugmaker's offices in Berlin, Germany, on Friday, Dec. 1, 2017. Bayer is ready to spend more money on deals and research that will help make it into a cancer company as the companys blockbuster blood-thinner Xarelto nears the final years of its patent life. Photographer: Krisztian Bocsi/Bloomberg via Getty Images

Joerg Moeller, head of development at Bayer AG, speaks during a news conference at the drugmaker's offices in Berlin, Germany, on Friday, Dec. 1, 2017. Bayer is ready to spend more money on deals and research that will help make it into a cancer company as the companys blockbuster blood-thinner Xarelto nears the final years of its patent life. Photographer: Krisztian Bocsi/Bloomberg via Getty Images

see more

Liam Condon, board member at Bayer AG, looks on during a news conference as the drugmaker announces its full year results in Leverkusen, Germany, on Wednesday, Feb. 22, 2017. Demand for medicines such as the blood thinner Xarelto and the eye treatment Eylea boosted sales and profit. Photographer: Krisztian Bocsi/Bloomberg via Getty Images

Liam Condon, board member at Bayer AG, looks on during a news conference as the drugmaker announces its full year results in Leverkusen, Germany, on Wednesday, Feb. 22, 2017. Demand for medicines such as the blood thinner Xarelto and the eye treatment Eylea boosted sales and profit. Photographer: Krisztian Bocsi/Bloomberg via Getty Images

see more

An attendee wears a virtual reality (VR) headset to view an oncology tutorial at the Bayer AG offices in Berlin, Germany, on Friday, Dec. 1, 2017. Bayer is ready to spend more money on deals and research that will help make it into a cancer company as the companys blockbuster blood-thinner Xarelto nears the final years of its patent life. Photographer: Krisztian Bocsi/Bloomberg via Getty Images

An attendee wears a virtual reality (VR) headset to view an oncology tutorial at the Bayer AG offices in Berlin, Germany, on Friday, Dec. 1, 2017. Bayer is ready to spend more money on deals and research that will help make it into a cancer company as the companys blockbuster blood-thinner Xarelto nears the final years of its patent life. Photographer: Krisztian Bocsi/Bloomberg via Getty Images